"Wu Jian Shi Jia"was from Dai Tianzhang's Guang Wen Yi Lun in the Qing Dynasty.By combing the meaning of the word"Wu Jian Shi Jia"and the relevant theoretical views of physicians in the past dynasties,this article summarized the symptoms and treatment outcomes of"Wu Jian Shi Jia"and the situation of concomitant syndromes.The"Wu Jian"refers to epidemic pathogenic factors complicated by cold,wind,summer-heat,malaria,and dysentery,while the"Shi Jia"includes excess syndromes:complications with phlegm-fluid retention,food stagnation,depression,and blood stasis;deficiency syndromes:complications with spleen deficiency,kidney deficiency,and blood depletion;chronic disorders:complications with hernia,heart-stomach pain,and asthma.Additionally,this research expanded the scope of concomitant syndromes of epidemic diseases to accompanying dampness,dryness,toxicity,yin deficiency,and yang deficiency.The theory of"Wu Jian Shi Jia"holds significant literary and application value,enriching the theoretical framework of modern diagnosis and treatment of epidemic diseases.

Parkinson’s disease （PD） is a common chronic neurodegenerative disease with movement disorders as the main clinical manifestation. The nuclear factor-erythroid 2-related factor 2 （Nrf2）/heme oxygenase-1 （HO-1） signaling pathway is closely associated with the occurrence and progression of PD. TCM flavonoid monomers （luteolin， rutin， etc.）， alkaloids （camptothecin， sinomenine， and alkaloids extracted from Uncaria rhynchophylla）， terpenes （tanshinone ⅡA， carvacrol， paeoniflorin）， phenols （ellagic acid， rosmarinic acid）， saponins （ginsenoside RK1）， and traditional Chinese medicine compounds （Wuzi yanzong pill and PD formula-2） can resist oxidative stress damage， inhibit inflammatory responses and abnormal aggregation of α-synuclein， and regulate neurotrophic factors by activating the Nrf2/HO-1 signaling pathway， thereby alleviating dopaminergic neuronal damage.

OBJECTIVE To explore the willingness to pay （WTP） of Urumqi residents for community pharmacies’ medication guidance services and its influencing factors， so as to provide data support for the optimization of community pharmacy services and the establishment of a fee structure for medication guidance services. METHODS A stratified quota sampling method was employed to select 14 communities in Urumqi City. From April to June 2025， a combined offline and online questionnaire survey was conducted among adult residents in these communities. The contingent valuation method was used to construct three hypothetical scenarios （namely， basic， enhanced and extended services） of medication counselling in community pharmacies to assess residents’ WTP for these services. Binary Logistic regression was employed to analyze the influencing factors of WTP. RESULTS A total of 576 valid questionnaires were obtained. Under the scenarios of basic， enhanced and extended services， 38.54%， 49.65% and 67.19% of the respondents expressed WTP for the services， respectively. Occupational type， type of basic medical insurance， annual income， perception of pharmacists’ profession， and acceptance level of the service were identified as major influencing factors for WTP （P＜0.05）. CONCLUSIONS The willingness of residents in Urumqi to pay for medication counseling services provided by pharmacists in community pharmacies significantly increases with the enrichment of service content. It is recommended to incorporate basic medication counselling services provided by pharmacists in community pharmacies into medical insurance payment， while value-added services should be partially or fully self-paid by residents. Additionally， efforts should be made to strengthen the promotion of the professional and service value of licensed pharmacists， so as to facilitate the high-quality development of pharmaceutical care.

Objective:To evaluate the efficacy and safety of treatments in phase Ⅰ oncology clinical trials in patients with advanced non-small-cell lung cancer(NSCLC).Methods:We retrospectively analyzed the clinical data of 65 patients with advanced NSCLC who received phase Ⅰ antitumor trial drugs at the Clinical Trial Research Center of The First Affiliated Hospital of Bengbu Medical University from January 2020 to December 2023.The efficacy and occurrence of serious adverse events(SAEs)were analyzed.Results:The objective response rate(ORR)and disease control rate(DCR)were 9.2%and 61.4%,respectively,whereas the median progression-free survival(PFS)and overall survival(OS)were 2.9 and 15.1 months,respectively.Previously receiving second-line or more lines of treatment and SAE occurrence were independent risk factors for a shorter PFS(P<0.05).A history of smoking and previous second-line or more lines of treatment were inde-pendent risk factors for a shorter OS(P<0.05).The SAE incidence was 15.4%,and no treatment-related deaths occurred.Conclusions:Treat-ments in phase Ⅰ oncology clinical trials are beneficial for patients with advanced NSCLC.Patients with a higher number of previous treat-ment lines and those who experienced SAEs during the trial had a shorter PFS,whereas patients with no smoking history and fewer previous treatment lines had a longer overall survival.The overall safety of the treatments was acceptable.

"Wu Jian Shi Jia"was from Dai Tianzhang's Guang Wen Yi Lun in the Qing Dynasty.By combing the meaning of the word"Wu Jian Shi Jia"and the relevant theoretical views of physicians in the past dynasties,this article summarized the symptoms and treatment outcomes of"Wu Jian Shi Jia"and the situation of concomitant syndromes.The"Wu Jian"refers to epidemic pathogenic factors complicated by cold,wind,summer-heat,malaria,and dysentery,while the"Shi Jia"includes excess syndromes:complications with phlegm-fluid retention,food stagnation,depression,and blood stasis;deficiency syndromes:complications with spleen deficiency,kidney deficiency,and blood depletion;chronic disorders:complications with hernia,heart-stomach pain,and asthma.Additionally,this research expanded the scope of concomitant syndromes of epidemic diseases to accompanying dampness,dryness,toxicity,yin deficiency,and yang deficiency.The theory of"Wu Jian Shi Jia"holds significant literary and application value,enriching the theoretical framework of modern diagnosis and treatment of epidemic diseases.

Objective:To evaluate the efficacy and safety of treatments in phase Ⅰ oncology clinical trials in patients with advanced non-small-cell lung cancer(NSCLC).Methods:We retrospectively analyzed the clinical data of 65 patients with advanced NSCLC who received phase Ⅰ antitumor trial drugs at the Clinical Trial Research Center of The First Affiliated Hospital of Bengbu Medical University from January 2020 to December 2023.The efficacy and occurrence of serious adverse events(SAEs)were analyzed.Results:The objective response rate(ORR)and disease control rate(DCR)were 9.2%and 61.4%,respectively,whereas the median progression-free survival(PFS)and overall survival(OS)were 2.9 and 15.1 months,respectively.Previously receiving second-line or more lines of treatment and SAE occurrence were independent risk factors for a shorter PFS(P<0.05).A history of smoking and previous second-line or more lines of treatment were inde-pendent risk factors for a shorter OS(P<0.05).The SAE incidence was 15.4%,and no treatment-related deaths occurred.Conclusions:Treat-ments in phase Ⅰ oncology clinical trials are beneficial for patients with advanced NSCLC.Patients with a higher number of previous treat-ment lines and those who experienced SAEs during the trial had a shorter PFS,whereas patients with no smoking history and fewer previous treatment lines had a longer overall survival.The overall safety of the treatments was acceptable.

Neoadjuvant chemoradiotherapy (nCRT) followed by total mesorectal excision (TME) and adjuvant chemotherapy serves as a traditional standard treatment for locally advanced rectal cancer (LARC). However, such treatment suffers low pathological complete response (pCR) rates, which are merely less than 15%, and low anal-preservation rates, failing to meet the demand of patients for high quality of life. Recently, total neoadjuvant therapy (TNT) whereby postoperative adjuvant chemotherapy is performed preoperatively has further increased the pCR rate, gradually becoming a novel therapeutic approach. Nevertheless, the pCR rate of TNT remains below 30%. Presently, immune checkpoint inhibitors (ICIs) have been proved to be highly successful in treating various solid tumors, yet they are scarcely employed to treat LARC. In recent years, many clinical trials have been conducted to explore the application of nCRT combined with ICIs in the treatment of LARC. This paper reviews the advances in research on this therapy.

Objective To investigate the effects of denosumab on glucose-lipid metabolism and cardiovascular in patients with postmenopausal osteoporosis(POMP).Methods Patients diagnosed with POMP in Xinjiang Uygur Autonomous Region People's Hospital from 1 January 2017 to 31 August 2022 were selected,and the patients were divided into the desutumomab and atorvastatin calcium group(group A),the desutumomab group(group B),and the control group(group C)according to the drugs used,and the general data and laboratory examinations of the patients in the three groups were collected.General information and laboratory tests were collected from the three groups of patients,and basic information,bone metabolism,glucose metabolism,lipid metabolism,and myocardial injury indexes were compared among the three groups of patients.Results After 1 year of treatment,the alkaline phosphatase level of the three groups of patients decreased significantly compared with that before treatment(P<0.05),and the differences in lactate dehydrogenase(LDH)and fasting blood glucose levels of the three groups of patients after drug treatment were statistically significant(P<0.05),and compared with group C,the reduction of fasting blood glucose in group B was more significant,and the increase in LDH was more significant(P<0.05)after treatment.Comparison of creatine kinase(CK)level in group C and LDH level in group A before and after treatment within the group,the difference was statistically significant(P<0.05).Conclusion The effect of denosumab treatment on glucose metabolism in patients with POMP may be beneficial,and the use of denosumab may be a better choice for patients with diabetes combined with osteoporosis.The present study provides preliminary evidence that denosumab in combination with statin in patients with POMP resulted in lower LDH levels,whereas CK was elevated in patients treated with atorvastatin only,suggesting that denosumab may be more advantageous in regulating glucose metabolism,lipid metabolism,and the prevention of cardiovascular events.

Anlotinib has strong antiangiogenic effects and leads to vessel normalization.However,the"window period"characteristic in regulating vessel normalization by anlotinib cannot fully explain the long-term survival benefits achieved through combining it with other drugs.In this study,through RNA sequencing(RNA-seq)and label-free quantitative proteomics analysis,we discovered that anlotinib regulated the expression of components of the extracellular matrix(ECM),leading to a significant reduction in ECM stiffness.Our bioinformatic analysis revealed a potential positive relationship between the ECM pathway and gefitinib resistance,poor treatment outcomes for programmed death 1(PD-1)targeting,and unfavourable prognosis following chemotherapy in lung cancer patients.We administered anlotinib in combination with these antitumour drugs and visualized their distribution using fluorescent labelling in various tumour types.Notably,our results demonstrated that anlotinib prolonged the retention time and distribution of antitumour drugs at the tumour site.Moreover,the combination therapy induced notable loosening of the tumour tissue structure.This reduction was associated with decreased interstitial fluid pressure and tumour solid pressure.Additionally,we observed that anlotinib effectively suppressed the Ras homologue family member A(RhoA)/Rho-associated protein kinase(ROCK)signalling pathway.These findings suggest that,in addition to its antiangiogenic and vessel normalization effects,anlotinib can increase the distribution and retention of antitumour drugs in tumours by modulating ECM expression and physical properties through the RhoA/ROCK signalling pathway.These valuable insights contribute to the development of combination therapies aimed at improving tumour targeting in cancer treatment.